Zheng N - Search Results

1

Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells.

Xue G, Wang Z, Zheng N, Fang J, Mao C, Li X, Jin G, Ming X, Lu Y. Xue G, et al. Among authors: zheng n. Nat Biomed Eng. 2021 Nov;5(11):1306-1319. doi: 10.1038/s41551-021-00799-6. Epub 2021 Nov 1. Nat Biomed Eng. 2021. PMID: 34725506 Free PMC article.

2

Targeting the IL-9 pathway in cancer immunotherapy.

Zheng N, Lu Y. Zheng N, et al. Hum Vaccin Immunother. 2020 Oct 2;16(10):2333-2340. doi: 10.1080/21645515.2019.1710413. Epub 2020 Feb 10. Hum Vaccin Immunother. 2020. PMID: 32040369 Free PMC article. Review.

3

Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells.

Xue G, Zheng N, Fang J, Jin G, Li X, Dotti G, Yi Q, Lu Y. Xue G, et al. Among authors: zheng n. Cancer Cell. 2021 Dec 13;39(12):1610-1622.e9. doi: 10.1016/j.ccell.2021.09.011. Epub 2021 Oct 21. Cancer Cell. 2021. PMID: 34678150 Free PMC article.

4

hDirect-MAP: projection-free single-cell modeling of response to checkpoint immunotherapy.

Lu Y, Xue G, Zheng N, Han K, Yang W, Wang RS, Wu L, Miller LD, Pardee T, Triozzi PL, Lo HW, Watabe K, Wong STC, Pasche BC, Zhang W, Jin G. Lu Y, et al. Among authors: zheng n. Brief Bioinform. 2022 Mar 10;23(2):bbab575. doi: 10.1093/bib/bbab575. Brief Bioinform. 2022. PMID: 35037026 Free PMC article.

5

Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance.

Zheng N, Fang J, Xue G, Wang Z, Li X, Zhou M, Jin G, Rahman MM, McFadden G, Lu Y. Zheng N, et al. Cancer Cell. 2022 Sep 12;40(9):973-985.e7. doi: 10.1016/j.ccell.2022.08.001. Epub 2022 Aug 25. Cancer Cell. 2022. PMID: 36027915 Free PMC article.

6

Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy.

Xue G, Li X, Kalim M, Fang J, Jiang Z, Zheng N, Wang Z, Li X, Abdelrahim M, He Z, Nikiforov M, Jin G, Lu Y. Xue G, et al. Among authors: zheng n. Cancer Cell. 2024 May 13;42(5):780-796.e6. doi: 10.1016/j.ccell.2024.03.001. Epub 2024 Mar 21. Cancer Cell. 2024. PMID: 38518774

7

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy.

Kalim M, Jing R, Li X, Jiang Z, Zheng N, Wang Z, Wei G, Lu Y. Kalim M, et al. Among authors: zheng n. J Cell Immunol. 2024;6(1):22-50. doi: 10.33696/immunology.6.189. J Cell Immunol. 2024. PMID: 38883270 Free PMC article.

8

RPS23RG1 inhibits SORT1-mediated lysosomal degradation of MDGA2 to protect against autism.

Huo Y, Zhao D, Zhu X, Zheng N, Yang D, Meng J, Chen Y, Zhang YW. Huo Y, et al. Among authors: zheng n. Theranostics. 2025 Jan 1;15(4):1338-1352. doi: 10.7150/thno.100451. eCollection 2025. Theranostics. 2025. PMID: 39816685 Free PMC article.

9

AdipoRon ameliorates chronic ethanol induced cardiac necroptosis by reducing ceramide mediated mtROS.

Qian Y, Qi Y, Lin J, Zhang T, Mo L, Xue Q, Zheng N, Niu Y, Dong X, Shi Y, Jiang Y. Qian Y, et al. Among authors: zheng n. Free Radic Biol Med. 2025 Jan 11:S0891-5849(25)00018-8. doi: 10.1016/j.freeradbiomed.2025.01.018. Online ahead of print. Free Radic Biol Med. 2025. PMID: 39805512

10

Tailoring industrial enzymes for thermostability and activity evolution by the machine learning-based iCASE strategy.

Zheng N, Cai Y, Zhang Z, Zhou H, Deng Y, Du S, Tu M, Fang W, Xia X. Zheng N, et al. Nat Commun. 2025 Jan 11;16(1):604. doi: 10.1038/s41467-025-55944-5. Nat Commun. 2025. PMID: 39799136 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,434 results

Search Page

Filters